At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
V940 is made in a laboratory. It uses genes in your cancer to teach your immune system to fight the cancer. V940 is given as an injection into a muscle. Pembrolizumab boosts the ability of the immune system to find and kill cancer cells. It is given intravenously (by vein).
-
Researchers want to see if giving additional radiation therapy to standard treatment helps people with lung cancer to live longer. The people in this study have non-small cell lung cancer (NSCLC) that cannot be removed with surgery (inoperable cancer). The standard treatment includes image-guided radiation therapy (IGRT), chemotherapy, and immunotherapy with durvalumab. 
- A Phase 1 Study of IMA203 Cellular Therapy With mRNA-4203 in People With Cutaneous Melanoma or Synovial Sarcoma
Full Title A First-in-Human, Open-Label Trial to Evaluate the Combination of ACTengineTM IMA203 with mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengineTM IMA203-102)
Purpose
Researchers are seeking the best dose of mRNA-4203 to give with a cellular therapy in people with melanoma or sarcoma. The cellular therapy is called IMA203 and is custom-made from each patient’s white blood cells.
The people in this study have melanoma or synovial sarcoma that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their cancers have a protein called HLA-A*02:01.
IMA203 is made from T cells, which protect the body from infections, cancer, and other possible harms. Some cancers can block T cells from attacking cancer cells. We will collect some of your T cells and change them to help them find and kill your cancer cells. These modified T cells are called TCR (T cell receptor)-engineered T cells. Treatments made from them are called TCR T-cell therapies.
mRNA-4203 is a vaccine that may help activate the immune system to better target and kill cancer cells.
Who Can Join
To join this study, there are a few conditions. You must:
- Have HLA-A*02:01-positive metastatic or inoperable melanoma of the skin or synovial sarcoma.
- Have recovered from the serious side effects of previous treatments before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. James Smithy’s office at 646-888-6782.
Protocol
25-223Phase
Phase I (phase 1)Disease Status
Newly Diagnosed & Relapsed/RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06946225ClinicalTrials.gov
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
The purpose of this study is to compare the safety and effectiveness of adding duvelisib or CC-486 (oral azacitidine) to the usual chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) in people with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth; it is taken orally (by mouth).
-
Researchers want to see if adding autogene cevumeran to nivolumab is better than nivolumab alone to treat urothelial (bladder) cancer. The people in this study have muscle-invasive urothelial cancer (MIUC) that has been removed with surgery.
-
Researchers in this study are exploring the feasibility of making an immunotherapy in a laboratory using white blood cells (called lymphocytes or T cells) collected from the tumor of a patient with metastatic uveal melanoma. This is called autologous tumor-infiltrating lymphocyte (TIL) therapy. The TIL therapy being assessed in this study is called LN-144, and it is designed to activate white blood cells to attack the tumor.
-
Researchers are finding the best doses of valemetostat tosylate and datopotamab deruxtecan (Dato-DXd) to use in people with lung cancer. In a second part of the study, researchers are finding the best doses of valemetostat tosylate and trastuzumab deruxtecan (T-DXd) to use in people with digestive cancers.
-
Researchers want to see how well revumenib works against acute leukemia. The people in this study have acute leukemia that keeps growing after treatment. They also have a mutation (change) in the HOX gene, which is related to new or immature leukemia cells.
- A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People with Advanced Pancreatic Cancer and BRCA Mutations
Full Title SHARON: Study of Metastatic Cancers in Patients Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives
Purpose
The purpose of this study is to see whether the combination of melphalan, BCNU, vitamin B12b, and vitamin C, followed by autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer who have a BRCA1 and/or BRCA2 gene mutation. All of these treatments are given intravenously (by vein).
Melphalan and BCNU are both chemotherapy drugs that work by targeting the processes that cancer cells use to grow and spread. Vitamin B12b and vitamin C work together to block cancer cell energy production and prevent cancer cells from repairing the damage caused by the chemotherapy drugs. Autologous bone marrow stem cell infusion involves using healthy blood-forming cells from a patient’s own body to replace diseased or damaged bone marrow. The stem cell infusions will help decrease the side effects of the study treatment.
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have advanced pancreatic cancer.
- Patients must have responded to platinum-based chemotherapy.
- Patients must have a BRCA1 or BRCA2 mutation.
- At least 4 weeks must pass between the completion of prior treatment and receipt of the study treatment.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 to 71.
For more information about this study and to inquire about eligibility, please contact Dr. Kenneth Yu at 646-888-4188.
Protocol
20-504Phase
Phase I (phase 1)Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT04150042ClinicalTrials.gov